Back to Trades
Total Value
$219.8K
Net $219.8K bought
Filing Date
Feb 23, 2026
2 transactions
Purchases
$219.8K
2 transactions
Trade Summary
On Feb 19, 2026 through Feb 20, 2026, DEBBANE RAYMOND, Director, purchased $219.8K of LEXICON PHARMACEUTICALS, INC. (LXRX) across 2 transactions. The filing covers Common Stock and reflects net buying of $219.8K. Reported prices ranged from $1.44 to $1.48. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- LEXICON PHARMACEUTICALS, INC.
- Ticker Symbol
- LXRX
- CIK
- 0001062822
Insider Information
- Name
- DEBBANE RAYMOND
- Role
- Director
- Location
- THE WOODLANDS, TX
Filing Details
- Filing Date
- Feb 23, 2026
- Transaction Date
- Feb 19, 2026
- Accession Number
- 0001062822-26-000031
- Form Type
- 4
- Net Trading Amount
- $219.8K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Feb 19, 2026 | Common Stock | 50,000 | $1.44 | Purchase | $72.0K |
| Feb 20, 2026 | Common Stock | 100,000 | $1.48 | Purchase | $147.8K |
Want live alerts when DEBBANE RAYMOND trades again?
Download Insider Trades to track LXRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.425 to $1.455 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.
- (F2)Represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.49 per share. The reporting person hereby undertakes to provide to the issuer, a security holder of the issuer or the SEC staff, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in this footnote.